News & Updates

Show Multimedia Only

Even low-risk diabetes patients obtain renal, mortality benefits with SGLT2 inhibitors

30 May 2025 by

Sodium-glucose cotransporter-2 (SGLT2) inhibitors help reduce the risk of lung function decline and mortality in a low-risk population of patients with type 2 diabetes (T2D) who have normal or low BMI, as shown in a single-centre retrospective study from Korea.

Even low-risk diabetes patients obtain renal, mortality benefits with SGLT2 inhibitors

30 May 2025

Growth hormone treatment beneficial to girls with Turner syndrome, growth hormone deficiency

30 May 2025

Growth hormone therapy appears to boost height and growth rate in girls with Turner Syndrome (TS) or growth hormone deficiency (GHD), with pronounced effect seen in the first year of treatment, according to a case-control study.

Growth hormone treatment beneficial to girls with Turner syndrome, growth hormone deficiency

30 May 2025

High E2 levels after IVF up risk of glucose metabolic dysfunction in children

29 May 2025

During early pregnancy, high levels of maternal estradiol (E2) appear to contribute to altered glucose metabolism and greater metabolic risks in children conceived via in vitro fertilization (IVF), reports a recent study.

High E2 levels after IVF up risk of glucose metabolic dysfunction in children

29 May 2025

T2D treatment goal shifts from glucose centricity to end-organ protection

28 May 2025 by

With the advent of disease-modifying agents such as tirzepatide, the current treatment goal for type 2 diabetes (T2D) extends beyond merely managing glycaemic levels to focusing on a broader approach that emphasizes end-organ protection.

T2D treatment goal shifts from glucose centricity to end-organ protection

28 May 2025

High, increasing BMI ups risk of adulthood OSA

26 May 2025 by

Individuals with high or continuously increasing BMI from childhood to middle age are at greater risk of developing obstructive sleep apnoea (OSA) later in life, reveals a study.

High, increasing BMI ups risk of adulthood OSA

26 May 2025

Novel GLP-1/FGF21 dual agonist shows promise in treatment of MASLD with T2DM

26 May 2025

The glucagon-like peptide-1 (GLP-1) and fibroblast growth factor 21 (FGF21) dual agonist HEC88473 demonstrates an acceptable safety profile and potential efficacy in the management of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM).

Novel GLP-1/FGF21 dual agonist shows promise in treatment of MASLD with T2DM

26 May 2025

No APHINITY between statin use and survival outcomes in early HER2-positive breast cancer

26 May 2025 by

Statin use was not associated with improved survival outcomes in the phase III APHINITY trial investigating the addition of pertuzumab to trastuzumab and chemotherapy as adjuvant treatment for patients with early HER2-positive breast cancer (BC).

No APHINITY between statin use and survival outcomes in early HER2-positive breast cancer

26 May 2025

Neonatal vitamin D status linked to mental disorder risks

25 May 2025

Individuals with vitamin D deficiency as neonates face a heightened risk of mental disorders, according to a study.

Neonatal vitamin D status linked to mental disorder risks

25 May 2025

Low HDL-C levels may heighten risk of acromegaly

24 May 2025

Individuals with low high-density lipoprotein cholesterol (HDL-C) levels face an increased risk of acromegaly, according to a large retrospective study from Korea.

Low HDL-C levels may heighten risk of acromegaly

24 May 2025

Tirzepatide boasts lower risk of GI side effects vs other GLP1-RAs

23 May 2025 by

The use of tirzepatide delivers a better safety profile when compared to other glucagon-like peptide-1 receptor agonists (GLP-1RAs), as shown by the lower risk of gastrointestinal (GI) side effects associated with its use, reports a real-world study presented at DDW 2025.

Tirzepatide boasts lower risk of GI side effects vs other GLP1-RAs

23 May 2025

News & Updates

Filter by Specialty:

Specialty:

Even low-risk diabetes patients obtain renal, mortality benefits with SGLT2 inhibitors

Even low-risk diabetes patients obtain renal, mortality benefits with SGLT2 inhibitors

Growth hormone treatment beneficial to girls with Turner syndrome, growth hormone deficiency

Growth hormone treatment beneficial to girls with Turner syndrome, growth hormone deficiency

High E2 levels after IVF up risk of glucose metabolic dysfunction in children

High E2 levels after IVF up risk of glucose metabolic dysfunction in children

T2D treatment goal shifts from glucose centricity to end-organ protection

T2D treatment goal shifts from glucose centricity to end-organ protection

High, increasing BMI ups risk of adulthood OSA

High, increasing BMI ups risk of adulthood OSA

Novel GLP-1/FGF21 dual agonist shows promise in treatment of MASLD with T2DM

Novel GLP-1/FGF21 dual agonist shows promise in treatment of MASLD with T2DM

No APHINITY between statin use and survival outcomes in early HER2-positive breast cancer

No APHINITY between statin use and survival outcomes in early HER2-positive breast cancer

Neonatal vitamin D status linked to mental disorder risks

Neonatal vitamin D status linked to mental disorder risks

Low HDL-C levels may heighten risk of acromegaly

Low HDL-C levels may heighten risk of acromegaly

Tirzepatide boasts lower risk of GI side effects vs other GLP1-RAs

Tirzepatide boasts lower risk of GI side effects vs other GLP1-RAs